WO2001024782A3 - Pharmazeutisches mittel zur behandlung von kachexie und/oder kardiogenem schock - Google Patents

Pharmazeutisches mittel zur behandlung von kachexie und/oder kardiogenem schock Download PDF

Info

Publication number
WO2001024782A3
WO2001024782A3 PCT/DE2000/003481 DE0003481W WO0124782A3 WO 2001024782 A3 WO2001024782 A3 WO 2001024782A3 DE 0003481 W DE0003481 W DE 0003481W WO 0124782 A3 WO0124782 A3 WO 0124782A3
Authority
WO
WIPO (PCT)
Prior art keywords
cachexia
cardiogenic shock
treatment
pharmaceutical agent
chronic
Prior art date
Application number
PCT/DE2000/003481
Other languages
English (en)
French (fr)
Other versions
WO2001024782A2 (de
Inventor
Hans-Dieter Volk
Stefan Anker
Original Assignee
Max Delbrueck Centrum
Volk Hans Dieter
Stefan Anker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum, Volk Hans Dieter, Stefan Anker filed Critical Max Delbrueck Centrum
Priority to AU16462/01A priority Critical patent/AU1646201A/en
Publication of WO2001024782A2 publication Critical patent/WO2001024782A2/de
Publication of WO2001024782A3 publication Critical patent/WO2001024782A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Die Erfindung betrifft ein Mittel zur Behandlung von Kachexie infolge chronischer Herzinsuffizienz, Leberzirrhose, chronisch obstruktiver Lungenerkrankung oder chronischer Niereninsuffuzienz und/oder von kardiogenem Schock, das eine effektive Menge eines zur Immunsuppression geeigneten Stoffes oder Stoffgemisches enthält. Dieses Mittel ermöglicht eine neue Therapiemethode für die Therapie von Gewichtsverlust aufgrund einer Erkrankung (Kachexie) und für die Therapie des kardiogenen Schocks (schwere Dekompensation nach Akutem Myokardinfarkt).
PCT/DE2000/003481 1999-10-06 2000-10-04 Pharmazeutisches mittel zur behandlung von kachexie und/oder kardiogenem schock WO2001024782A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU16462/01A AU1646201A (en) 1999-10-06 2000-10-04 Pharmaceutical agent for the treatment of cachexia and/or cardiogenic shock

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19948126.1 1999-10-06
DE19948126A DE19948126A1 (de) 1999-10-06 1999-10-06 Pharmazeutisches Mittel zur Behandlung von Kachexie und/oder kardiogenem Schock

Publications (2)

Publication Number Publication Date
WO2001024782A2 WO2001024782A2 (de) 2001-04-12
WO2001024782A3 true WO2001024782A3 (de) 2002-04-11

Family

ID=7924678

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2000/003481 WO2001024782A2 (de) 1999-10-06 2000-10-04 Pharmazeutisches mittel zur behandlung von kachexie und/oder kardiogenem schock

Country Status (3)

Country Link
AU (1) AU1646201A (de)
DE (1) DE19948126A1 (de)
WO (1) WO2001024782A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
BRPI0413326A (pt) 2003-08-04 2006-10-10 Bristol Myers Squibb Co métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel
JP2008517584A (ja) 2004-08-16 2008-05-29 アディポジェン ファーマシューティカルズ ピーティーワイ リミテッド 代謝調節薬剤およびそのための使用
CA2660690A1 (en) * 2006-08-22 2008-02-28 Novartis Ag Treatment of fibrosing disorders
JP2010519309A (ja) * 2007-02-20 2010-06-03 ノバルティス アーゲー 脂質キナーゼおよびｍＴＯＲのデュアル阻害剤としてのイミダゾキノリン
EP2883883A1 (de) * 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutische Ziele und Mittel zur Behandlung von ischämiebedingten Reperfusionsschäden
CN111905103A (zh) * 2019-05-10 2020-11-10 深圳瑞健生命科学研究院有限公司 一种治疗肌萎缩侧索硬化的方法和药物

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005541A1 (en) * 1988-11-23 1990-05-31 The Regents Of The University Of Michigan Immunotherapy involving cd28 stimulation
WO1995001348A2 (en) * 1993-07-02 1995-01-12 Celgene Corporation Imides as inhibitors of tnp alpha
JPH08169846A (ja) * 1994-10-21 1996-07-02 Chuzo Kishimoto Ｉｌ−６産生に起因する疾患の治療剤
EP0791359A1 (de) * 1994-10-21 1997-08-27 Chugai Seiyaku Kabushiki Kaisha Heilmittel gegen von il-6 produktion verurschten krankheiten
WO1999036541A1 (en) * 1998-01-14 1999-07-22 Smithkline Beecham Corporation INTERLEUKIN-1 RECEPTOR ANTAGONIST BETA (IL-1RAβ)
EP0937460A2 (de) * 1994-04-12 1999-08-25 Adolor Corporation Verwendung eines Mittels gegen Durchfall für die Zubereitung eines Medikaments für die Behandlung von Entzündungen
WO1999047512A1 (en) * 1998-03-16 1999-09-23 Colgene Corporation 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines
WO1999058510A1 (en) * 1998-05-11 1999-11-18 Takeda Chemical Industries, Ltd. Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005541A1 (en) * 1988-11-23 1990-05-31 The Regents Of The University Of Michigan Immunotherapy involving cd28 stimulation
WO1995001348A2 (en) * 1993-07-02 1995-01-12 Celgene Corporation Imides as inhibitors of tnp alpha
EP0937460A2 (de) * 1994-04-12 1999-08-25 Adolor Corporation Verwendung eines Mittels gegen Durchfall für die Zubereitung eines Medikaments für die Behandlung von Entzündungen
JPH08169846A (ja) * 1994-10-21 1996-07-02 Chuzo Kishimoto Ｉｌ−６産生に起因する疾患の治療剤
EP0791359A1 (de) * 1994-10-21 1997-08-27 Chugai Seiyaku Kabushiki Kaisha Heilmittel gegen von il-6 produktion verurschten krankheiten
WO1999036541A1 (en) * 1998-01-14 1999-07-22 Smithkline Beecham Corporation INTERLEUKIN-1 RECEPTOR ANTAGONIST BETA (IL-1RAβ)
WO1999047512A1 (en) * 1998-03-16 1999-09-23 Colgene Corporation 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines
WO1999058510A1 (en) * 1998-05-11 1999-11-18 Takeda Chemical Industries, Ltd. Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 70, no. 2, August 1999 (1999-08-01), pages 183 - 197, ISSN: 0002-9165 *
ANKER S D ET AL: "ELEVATED SOLUBLE CD14 RECEPTORS AND ALTERED CYTOKINES IN CHRONIC HEART FAILURE", AMERICAN JOURNAL OF CARDIOLOGY, CAHNERS PUBLISHING CO., NEWTON, MA,, US, vol. 79, no. 10, 1997, pages 1426 - 1430, XP000971579, ISSN: 0002-9149 *
CAMARGO P R ET AL:: "FAVORABLE EFFECTS OF IMMUNOSUPPRESSIVE THERAPY IN CHILDREN WITH DILATED CARDIOMYOPATHY AND ACTIVE MYOCARDITIS", PEDRIATIC CARDIOLOGY, vol. 16, 1995, pages 61 - 68, XP001038544 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1994, GREKOVA T I ET AL: "Comparative efficacy of peptide drugs finoptin, levamisole, and prednisolone in experimental immune cardiogenic shock.", XP002186379, Database accession no. PREV199598127824 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; August 1999 (1999-08-01), YEH SHING-SHING ET AL: "Geriatric cachexia: The role of cytokines.", XP002186380, Database accession no. PREV199900382461 *
HASPER D ET AL: "INFLAMMATORISCHE MEDIATOREN BEI PATIENTEN MIT BIVENTRIKULAEREN ASSIST-DEVICE-SYSTEMEN INFLAMMATORY MEDIATORS IN PATIENTS WITH BIVENTRICULAR ASSIST DEVICESYSTEMS", ZEITSCHRIFT FUER KARDIOLOGIE, DEUTSCHE GESELLSCHAFT FUER KARDIOLOGIE, DE, vol. 85, no. 11, November 1996 (1996-11-01), pages 820 - 827, XP001037510, ISSN: 0300-5860 *
LOPRINZI C L ET AL: "RANDOMIZED COMPARISON OF MEGESTROL ACETATE VERSUS DEXAMETHASONE VERSUS FLUOXYMESTERONE FOR THE TREATMENT OF CANCER ANOREXIA/CACHEXIA", JOURNAL OF CLINICAL ONCOLOGY, vol. 17, no. 10, 1999, pages 3299 - 3306, XP001037949 *
PATENT ABSTRACTS OF JAPAN vol. 1996, no. 11 29 November 1996 (1996-11-29) *
PATOLOGICHESKAYA FIZIOLOGIYA I EKSPERIMENTAL'NAYA TERAPIYA, no. 3, 1994, pages 35 - 37, ISSN: 0031-2991 *
ROFE A M ET AL: "PREVENTION OF ADJUVANT-INDUCED CACHEXIA IN RATS BY CYCLOSPORIN A", IMMUNOLOGY AND CELL BIOLOGY, vol. 68, 1990, pages 63 - 69, XP001038545 *

Also Published As

Publication number Publication date
AU1646201A (en) 2001-05-10
DE19948126A1 (de) 2001-04-12
WO2001024782A2 (de) 2001-04-12

Similar Documents

Publication Publication Date Title
PL354093A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
HUP0200760A2 (en) Compounds and methods for therapy and diagnosis of lung cancer
WO2001034088A3 (en) Cardiac device for electrical and chemical regulation, and vasoactive intestinal peptide for treatment of cardiopulmonary disorders
AU2001261007A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
ITMI20000312A0 (it) Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva
ZA99693B (en) Compounds for therapy and diagnosis of lung cancer and methods for their use.
AU4185100A (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
CA2360248A1 (en) Combinations of formoterol and a tiotropium salt
WO1999008739A3 (en) Multi-lumen cannula
WO2002100390A3 (en) Improved method of treating the syndrome of coronary heart disease risk factors in humans
AU4583899A (en) Nasal administration of sildenafil for the treatment of erectile dysfunction
WO2001024782A3 (de) Pharmazeutisches mittel zur behandlung von kachexie und/oder kardiogenem schock
AU2002218770A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001074329A3 (en) Sustained release beadlets containing stavudine
WO2000020041A8 (en) Removal of preexisting antibodies to enhance the effectiveness of a therapeutic viral immunogenic agent
AU2001259062A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
CA2344910A1 (en) Method for treating renal disease, and pharmaceutical composition for treating renal disease
WO2001090136A3 (en) Triterpenoid derivatives
HUP0102388A3 (en) Use of diazepinoindole derivatives for the preparation of pharmaceutical composition treating chronic obstructive pulmonary disease
AU2001273149A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU4228000A (en) Methods and compositions for the treatment and prevention of lung disease
CA2304698A1 (en) Endothelin antagonist and beta receptor blocking agent as combined preparations
WO1997035568A3 (en) Diclofenac/gamma-cyclodextrin inclusion compounds
AU2001273127A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
CA2370501A1 (en) Pharmaceutical composition for the therapy of lower urinary tract symptoms

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP